CD47‐blocking antibodies (anti‐CD47) can prevent this inhibition and promote macrophage‐mediated phagocytosis of cancer cells.[83] However, monoclonal antibodies are easily cleared by the body, thus leading to higher therapeutic dose requirements to overcome drug degradation caused by anti‐CD47. This evidence concerns the gene CD47 and cancer.